Determination of Rates and Severity of cytokine release syndrome/Neurologic toxicities and Efficacy and Utility of toxicity management strategies of blinatumomab therapy
Latest Information Update: 06 Dec 2019
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 06 Dec 2019 New trial record
- 06 Nov 2019 Results assessing rates,severity of cytokine release syndrome and neurologic toxicities and efficacy of toxicity management strategies,released in 61st Annual Meeting and Exposition of the American Society of Hematology